Background:Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity.We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscop...Background:Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity.We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscopic ultrasound(EUS),and if these measurements correlate with metabolic disease burden.Methods:This was a retrospective analysis of patients who underwent celiac artery mesenteric fat measurement with endosonography(CAMEUS)measurement at a tertiary referral center,and a validation prospective trial of patients with obesity and nonalcoholic steatohepatitis who received paired EUS exams with CAMEUS measurement before and after six months of treatment with an intragastric balloon.Results:CAMEUS was measured in 154 patients[56.5%females,mean age 56.5±18.0years,body mass index(BMI)29.8±8.0 kg/m^(2)]and was estimated at 14.7±6.5mm.CAMEUS better correlated with the presence of non-alcoholic fatty liver disease(NAFLD)(R^(2)=0.248,P<0.001)than BMI(R^(2)=0.153,P<0.001),and significantly correlated with metabolic parameters and diseases.After six months of intragastric balloon placement,the prospective cohort experienced 11.7%total body weight loss,1.3 points improvement in hemoglobin A1c(P=0.001),and a 29.4%average decrease in CAMEUS(−6.4±5.2mm,P<0.001).CAMEUS correlated with improvements in weight(R^(2)=0.368),aspartate aminotransferase to platelet ratio index(R^(2)=0.138),and NAFLD activity score(R^(2)=0.156)(all P<0.05).Conclusions:CAMEUS is a novel measure that is significantly correlated with critical metabolic indices and can be easily captured during routine EUS to risk-stratify susceptible patients.This station could allow for EUS access to sampling and therapeutics of this metabolic region.展开更多
文摘Background:Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity.We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscopic ultrasound(EUS),and if these measurements correlate with metabolic disease burden.Methods:This was a retrospective analysis of patients who underwent celiac artery mesenteric fat measurement with endosonography(CAMEUS)measurement at a tertiary referral center,and a validation prospective trial of patients with obesity and nonalcoholic steatohepatitis who received paired EUS exams with CAMEUS measurement before and after six months of treatment with an intragastric balloon.Results:CAMEUS was measured in 154 patients[56.5%females,mean age 56.5±18.0years,body mass index(BMI)29.8±8.0 kg/m^(2)]and was estimated at 14.7±6.5mm.CAMEUS better correlated with the presence of non-alcoholic fatty liver disease(NAFLD)(R^(2)=0.248,P<0.001)than BMI(R^(2)=0.153,P<0.001),and significantly correlated with metabolic parameters and diseases.After six months of intragastric balloon placement,the prospective cohort experienced 11.7%total body weight loss,1.3 points improvement in hemoglobin A1c(P=0.001),and a 29.4%average decrease in CAMEUS(−6.4±5.2mm,P<0.001).CAMEUS correlated with improvements in weight(R^(2)=0.368),aspartate aminotransferase to platelet ratio index(R^(2)=0.138),and NAFLD activity score(R^(2)=0.156)(all P<0.05).Conclusions:CAMEUS is a novel measure that is significantly correlated with critical metabolic indices and can be easily captured during routine EUS to risk-stratify susceptible patients.This station could allow for EUS access to sampling and therapeutics of this metabolic region.
